Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
PureTech Health ( (GB:PRTC) ) has provided an update.
PureTech Health’s Founded Entity, Seaport Therapeutics, has published new research demonstrating the GlyphTM platform’s ability to enhance drug absorption through the lymphatic system, achieving up to 55% absorption for the immunomodulatory drug mycophenolic acid. This research underscores the potential of the Glyph platform to improve drug bioavailability and reduce side effects by bypassing first-pass metabolism, offering significant implications for drug design and therapeutic applications.
More about PureTech Health
PureTech Health is a clinical-stage biotherapeutics company focused on developing new classes of medicine to treat severe diseases. The company, through its research and development team and extensive network, has developed a pipeline of 29 therapeutics, including three FDA-approved drugs. PureTech’s innovations are advanced internally and through its Founded Entities.
YTD Price Performance: -4.13%
Average Trading Volume: 638,203
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £348.1M
See more insights into PRTC stock on TipRanks’ Stock Analysis page.
